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Abstract
Psoriasis is a chronic, immune-mediated skin disease affecting 2–3% of Caucasians. Recent genetic association studies have
identified multiple psoriasis risk loci; however, most of these loci contribute only modestly to disease risk. In this study, we
investigated whether a genetic risk score (GRS) combining multiple loci could improve psoriasis prediction. Two approaches
were used: a simple risk alleles count (cGRS) and a weighted (wGRS) approach. Ten psoriasis risk SNPs were genotyped in
2815 case-control samples and 858 family samples. We found that the total number of risk alleles in the cases was
significantly higher than in controls, mean 13.16 (SD 1.7) versus 12.09 (SD 1.8), p=4.577610
240. The wGRS captured
considerably more risk than any SNP considered alone, with a psoriasis OR for high-low wGRS quartiles of 10.55 (95% CI
7.63–14.57), p=2.010610
265. To compare the discriminatory ability of the GRS models, receiver operating characteristic
curves were used to calculate the area under the curve (AUC). The AUC for wGRS was significantly greater than for cGRS
(72.0% versus 66.5%, p=2.13610
28). Additionally, the AUC for HLA-C alone (rs10484554) was equivalent to the AUC for all
nine other risk loci combined (66.2% versus 63.8%, p=0.18), highlighting the dominance of HLA-C as a risk locus. Logistic
regression revealed that the wGRS was significantly associated with two subphenotypes of psoriasis, age of onset
(p=4.91610
26) and family history (p=0.020). Using a liability threshold model, we estimated that the 10 risk loci account
for only11.6% of the genetic variance in psoriasis. In summary, we found that a GRS combining 10 psoriasis risk loci
captured significantly more risk than any individual SNP and was associated with early onset of disease and a positive family
history. Notably, only a small fraction of psoriasis heritability is captured by the common risk variants identified to date.
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Introduction
Psoriasis is a chronic, immune mediated skin disease, which
affects approximately 2–3% of Caucasians [1]. A number of
studies have supported the finding that genetic predisposition has a
critical role in the development of psoriasis [2,3]. Identification of
psoriasis susceptibility genes is the key to understanding its
pathogenesis and improving its treatment [2]. By using linkage
analysis and recent genome-wide association studies (GWAS),
several loci have been identified as risk factors for the development
of psoriasis [4–13]. Among them, the HLA-Cw6 allele has been
studied for many years and been known to confer the greatest
genetic effect in Caucasians, particularly for early onset cases [14].
However, the penetrance of HLA-Cw6 was estimated to be only
10%, suggesting HLA-Cw6 alone was insufficient to explain the
disease [15]. Additional non-MHC susceptibility loci have been
identified; however, when examined individually each of these loci
only confer modest disease risk and is of limited utility in disease
prediction. Previous studies have shown that combining multiple
loci with modest effects into a global genetic risk score (GRS)
might improve identification of persons who are at risk for
common complex diseases [16–18]. In this study, we examine the
discriminatory and predictive ability of a psoriasis GRS and
investigate the relationship between the GRS and several psoriasis
subphenotypes such as age of onset, family history of psoriasis,
type of psoriasis (plaque vs. guttate), and psoriatic arthritis. In
addition, we evaluate possible pair-wise genetic interactions and
estimate the proportion of genetic variance explained by the
known risk alleles.
Methods
Subjects
The study population and source are shown in Table 1. All
participants provided written informed consent with approval
from either the Committee on Human Research at the University
of California, San Francisco or the Human Research Protection
Office at Washington University, St. Louis. In total, the case-
control cohort consisted of 731 unrelated cases and 2084 unrelated
controls of European ancestry. A total of 1104 case-control
samples (642 from University of California San Francisco (UCSF)
and 462 from Washington University in St. Louis (WashU)) were
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samples obtained from studies 66 and 67 of illumina iControlDB
were genotyped on Human Hap550 BeadChip. Psoriasis cases
were 50.4% female, had mean age of onset 24.6 yrs (SD 15.5), and
had a positive family history of psoriasis, defined as at least one
affected first-degree relative, of 76.7%. Family samples from
WashU consisted of 281 families with at least 1 sibling diagnosed
with psoriasis. This sample included 225 unaffected subjects and
633 affected subjects (among the 633 affected subjects, 261
probands were also included as cases in the case-control cohort).
Almost all the families were nuclear, two generation families
consisting of children and their parents, and thus nearly all the
subjects were first degree relatives. The mean number of affected
subjects per family was 2.32 (0.71), and the mean number of
unaffected subjects per family was 1.24 (0.44).
Selection of genetic risk factors and quality control
We selected the psoriasis risk alleles from GWAS demonstrating
p,5610
27 and from large cohort studies with evidence of
replication at p,0.05 in at least one independent study. In total,
11 SNPs shown to be associated with psoriasis in previous GWAS
or large cohort studies were selected for analysis (Table S1). For
case-control samples, all 11 SNPs were successfully genotyped by
the Illumina GoldenGate assay. All 1104 samples passed a quality
control check (Illumina GenTrain score . 0.5, MAF.0.01,
Hardy-Weinberg Equilibrium, p.0.0001). We further removed
the suspected duplicates using an Identity-By-State and Identity-
By-Descent check (15 subjects from cases and 3 from controls).
Family samples were genotyped using the iPLEX chemistry on the
Sequenom platform according to the manufacturer’s instructions
(Sequenom, San Diego, CA).
Prior to merging, the iControlDB data were filtered for indivi-
duals with ,90% genotyping and SNPs with ,90% genotyping,
MAF ,1%, or HWE p-value ,0.00001. Three SNPs genotyped
by the Illumina GoldenGate assay but not present in the Human
Hap550 BeadChip were imputed by the program IMPUTE2
[19,20], using both HapMap (NCBI Build 36 (db126b)) CEU data
and 1000 Genomes as a reference haplotype set. Two SNPs
(rs17728338, rs6125829) showed high imputation confidence
(98.7% and 99.5%). One SNP rs597980 with low imputation
confidence (79.9%) was excluded from further analysis. Two SNPs
(rs11209026 and rs10484554) had missing genotyping data (17/
1711 and 36/1711, respectively) in the iControlDB dataset. We
use IMPUTE2 to impute the missing genotypes for the two SNPs.
Sixteen samples for rs11209026 and thirty-two samples for
rs10484554 were accurately imputed.
To correct for stratification of northwest vs. southeast European
ancestry, cases and controls were genotyped for 46 ancestry
informative markers (AIMs) which comprised a subset of those
previously reported [21]. All of these 46 SNPs were also present on
the Hapmap 550k platform used by iControlDB. Forty AIMs passed
the quality control criteria (GenTrain score .0.5, MAF.0.01 and
HWE, P.0.0001). We evaluated these AIMs on a test cohort of
individuals from geographically distinct areas of Europe and
validated their ability to distinguish northwest–southeast ancestry
(data not shown). Principal component analysis as implemented in
EIGENSTRAT was used to analyze the samples [22]. ANOVA
statistics for population differences along the eigenvectors demon-
strated that cases and controls did not differ on the first three
principal components. However, there was a significant effectof case
status on the fourth principal component (p=0.01). No significant
difference between cases and controls was observed for any of the
remaining principal components. The first four principal compo-
nents were used as covariates for ancestry adjustment.
Genetic risk score computation
Two approaches were used to calculate the GRS: a simple risk
alleles count method (count GRS, cGRS) and a weighted method
(weighted GRS, wGRS).The wGRS weights each risk allele by the
logarithm odds ratio (Log(OR)) for that allele in our dataset. Thus,
the wGRS is a linear combination of the number of risk alleles
weighted by the Log(OR) as coefficients. For example, two IL12B
risk alleles contribute 26Log(1.59) =0.928 to the wGRS. For a
protective SNP, the risk alleles are the major alleles. In order to
reduce the bias caused by missing data, we did not include any
subjects who had one or more missing genotypes in generating the
GRS. Because of the extremely low rate of missing data to start
with, only 7 cases and 89 controls were removed by this process.
Percentage of genetic variance explained
The percentage of genetic variance was estimated under a
liability threshold model [23,24]. This model assumes that
psoriasis has an underlying liability score which is normally
distributed with mean 0 and variance 1. We assumed a psoriasis
prevalence of 2.5% in the general population. To calculate the
threshold for each genotype, we used allele frequencies from
controls and an effect size corresponding to the OR from our
analysis.
Subphenotype definitions
Determination of plaque versus guttate psoriasis was made by a
dermatologist. Age of psoriasis onset was self-reported by subjects.
A positive family history was defined as at least one first degree
family member affected with psoriasis. The presence of psoriatic
arthritis was defined as subjects reporting psoriatic arthritis
diagnosed by a rheumatologist or dermatologist.
Statistical Analysis
An R software package (http://www.r-project.org/) was used
for logistic regression analysis, odds ratio estimation and
comparison of ROC curves. The Hardy-Weinberg equilibrium
test, pair-wise interactions test and the association test for
Table 1. Case-control population, family subjects and source.
Case-control
samples
N (Psoriasis
Case)
N
(Control)
Genotyping
platform
UCSF and
WashU
731 373 Illumina Goldengate
Assay
Illumina’s
iControlDB
NA 1711 Hapmap 550k BeadChip
Total 731 2084 _
Family
subjects
N (Affected
family
members)
N (unaffected
family
members) Genotyping platform
WashU 633* 225{ Sequenom iPLEX
*Among the 633 affected family subjects, 261 probands were also included as
cases (subset of 731) in case-control samples.
{ Note: The 225 unaffected family subjects were not included in generating the
risk allele odds ratios.
UCSF: University of California San Francisco; WashU: Washington University in
St. Louis
Illumina’s iControlDB: an online database of genotype and phenotype data
from individuals that can be used as controls in association studies. These data
are generated from Illumina genotyping products.
doi:10.1371/journal.pone.0019454.t001
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parametric Mann-Whitney test was used to compare the mean
number of risk alleles in cases-control population and the mean
wGRS in family samples. Correlation between the wGRS of
affected and unaffected family members within families was
measured using a Spearman correlation test. Cochran-Armitage
trend test was used to evaluate association of wGRS quartiles with
psoriasis. All the association tests were adjusted by gender and first
four principal components.
Results
Association between genetic risk alleles and psoriasis
Ten SNPs previously confirmed as psoriasis susceptibility loci
were evaluated in this study. Each SNP was in Hardy-Weinberg
equilibrium (P$0.05) in the control group. The results for each of
the ten risk alleles with the risk of psoriasis are shown in Table 2,
along with their adjusted odds ratios (ORs). Calculation of ORs
was performed using only case-control subjects. Associations range
from OR=3.07 (95% CI 2.61–3.61, 9.67610
242) for the SNP of
HLA-C to OR=1.06 (95% CI 0.89–1.25, p=0.5288) for IL13. All
the ORs are in the same direction for the risk alleles from
published discovery studies.
Genetic risk score association
To evaluate the cumulative effects of the ten highly replicated
psoriasis risk alleles, we developed a GRS by using either a simple
risk alleles count (cGRS) or a weighted (wGRS) approach. Figure 1
shows the distribution of number of psoriasis risk alleles in both
cases and controls, with a shift towards a higher number of risk
alleles in the cases. The mean number of risk alleles in the cases is
13.16 (SD 1.7) and the mean number of risk alleles in the controls
is 12.09 (SD 1.8), with a p=4.577610
240 by using the Mann-
Whitney test. To estimate the total amount of risk captured by the
genetic risk score, we calculated the odds ratios according to
wGRS quartile (Figure 2). There is a significant increase in
psoriasis ORs with increasing wGRS quartile, using the first
quartile as the reference group. The psoriasis OR, adjusted for
intra-European ancestry and gender, for high-low wGRS quartiles
is 10.55 (95% CI 7.63–14.57), with a trend p=2.010610
265.
We next measured and compared the discriminative power
attributable to the GRS by plotting receiver operating character-
istic (ROC) curves and calculating the area under the curve (AUC)
for the case-control samples. Our result shows that the wGRS is a
significantly better predictor than cGRS (Figure 3). The AUC for
wGRS is 72.0% (95%CI 69.9% –74.1%) versus 66.5% (95%CI
64.2% –68.8%) for cGRS, p=2.13610
28. Interestingly, the AUC
for HLA-C alone (rs10484554) is 66.2%, which is not statistically
different than the AUC for cGRS (66.5%, p=0.83), and even
slightly better than the AUC for the wGRS with HLA-C
excluded(63.8% p=0.18).
Associations with sub-phenotypes
Logistic regression was used to examine the relationship between the
wGRS and psoriasis subphenotypes, including age of onset, family
history of psoriasis, type of psoriasis, and psoriatic arthritis. As shown in
Table 3, two significant associations were found between the wGRS
and age of onset (p=4.91610
26)and family history of psoria-
sis(p=0.020), with corresponding ORs of 0.559(0.433–0.714) and
1.34(1.050–1.723). To further examine whether a positive family
history of psoriasis is associated with a higher wGRS, we calculated the
wGRS for affected and unaffected subjects from psoriasis families, and
compared the results to the wGRS for our unrelated case-control
samples. To eliminate the impact of unequal contribution due to family
size, the mean wGRS of affected subjects and unaffected sub-
jects within each family was first computed, resulting in a
‘‘wGRSfamily, affected’’ and ‘‘wGRSfamily, unaffected.’’ We found that the
mean wGRSfamily, affected in affected family subjects was significantly
higher than mean wGRS in cases without family history (4.92 versus
4.74, p=0.014). We also observed the mean wGRSfamily, unaffected was
slightly greater than in healthy controls (4.29 versus 4.20, p=0.071).
We also investigated the nature of intra-family vs inter-family variation
by plotting wGRSfamily, affected against wGRSfamily, unaffected in 180
families where data were available for both affected and unaffected
members. While significant variation in the wGRS is seen between
families, a strong positive correlation is seen between wGRS of
Table 2. Ten SNPs used to calculate the psoriasis genetic risk score in case-control samples.
Chr Gene SNP
Alleles
risk/nonrisk Risk alleles frequency OR* 95% CI* P-add*
Case Control
1 IL23R rs11209026 G/A 0.961 0.938 1.61 1.16–2.24 0.0044
1 LCE3C/3D rs4112788 C/T 0.701 0.635 1.37 1.18–1.58 2.31E-05
5 IL13 rs20541 C/T 0.813 0.806 1.06 0.89–1.25 0.5228
5 TNIP1/ANXA6 rs17728338 A/G 0.109 0.061 1.94 1.54–2.45 2.96E-08
5 IL12B rs3213094 G/A 0.853 0.784 1.59 1.33–1.91 5.80E-07
6 CDKAL1 rs6908425 C/T 0.823 0.792 1.22 1.03–1.45 0.0223
6 HLA-C rs10484554 T/C 0.351 0.158 3.07 2.61–3.61 9.67E-42
6 TNFAIP3 rs610604 C/T 0.364 0.336 1.12 0.98–1.29 0.1083
12 IL23A/STAT2 rs2066808 T/C 0.955 0.920 1.82 1.34–2.45 0.0001
20 ZNF313 rs6125829 G/T 0.646 0.616 1.13 0.98–1.30 0.0843
*P-value and ORs were adjusted for 4 principal components and gender.
Chr: Chromosome
SNP: Single nucleotide polymorphism
OR: Odds ratio
CI: Confidence intervals
P-add: P value under additive model
doi:10.1371/journal.pone.0019454.t002
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p=4.58610
25,F i g u r eS 1 ) .
Gene-gene Interactions
We also investigated all potential pair-wise interactions of the 10
risk alleles in both psoriasis cases versus controls and in case-only
analysis for each subphenotype. However, we did not find any
evidence of interactions between each SNP after Bonferroni
correction (data not shown).
The percentage of genetic variance explained
To estimate the percent of variance explained by each of the
psoriasis risk alleles, a previously described liability threshold
model was used [26,27].Our data show that HLA-C, IL12B and
TNIP1/ANXA6 were estimated to account for 6.7%, 1.3% and
1.0% of the genetic variance, whereas the remaining loci each
accounted for less than 1% of the genetic variance (Table 4).
Together, the 10 psoriasis risk loci were able to explain an
estimated 11.6% of the total genetic susceptibility to psoriasis.
Discussion
In this study, we developed a psoriasis genetic risk score (GRS)
which included 10 highly replicated loci from recent GWAS and
large cohort studies. We found that a weighted GRS, which
accounts for the odds ratio of each allele, is a better discriminator
of cases and controls than a simple count GRS. This agrees with
the results of Piccolo et al [26] who also found that a weighted
GRS could capture considerably more genetic risk compared to a
cGRS. Our weighted GRS was more associated with risk of
psoriasis than any single SNP alone, with persons in the highest
wGRS quartile having a greater than 10-fold increased risk of
psoriasis compared to persons in the lowest quartile.
Of the 10 SNPs evaluated in this study, the strongest signal was
found at the HLA-C locus at rs10484554, for which there was a
206% elevated risk of psoriasis with each risk allele. Notably, the
predictive capability for this single SNP was as good as that of the
other 9 non-MHC loci combined (Figure 3). Furthermore, our
study may actually underestimate the true effect of HLA-Cw6
because this allele has been shown to be more strongly associated
with psoriasis than its tag SNP rs10484554 used in this study [27].
The strong effect of this single locus on disease susceptibility stands
in contrast to other common diseases such as Type 2 diabetes,
coronary artery disease and prostate cancer, in which the risk is
more evenly distributed amongst multiple alleles [16,28,29]. Thus,
the genetic architecture underlying common complex diseases
may vary according to the disease. The 9 additional non-MHC
SNPs had a more modest effect on the risk of psoriasis, with each
allele conferring an elevated risk of 94% or lower. While these
alleles have little predictive power individually [30], their
combined addition to the HLA-C allele resulted in a composite
wGRS that displayed a slightly enhanced ability to discriminate
between people with and without psoriasis.
With regard to sub-phenotypes, our data show that the
weighted genetic risk score was higher amongst cases with an
earlier-onset of psoriasis and with a family history of disease. This
may largely be explained by the observation that the HLA-C locus
has a large impact on the wGRS, and several studies have
previously demonstrated that HLA-Cw6-positive patients show an
earlier disease onset and greater family aggregation than those
Figure 1. Distribution of the number of psoriasis risk alleles in cases (red) and controls (blue).
doi:10.1371/journal.pone.0019454.g001
Figure 2. Psoriasis odds ratios of weighted genetic risk score
quartiles relative to the first quartile. vertical bars correspond
to 95% confidence intervals. Ref.: reference. Q: quartile.
doi:10.1371/journal.pone.0019454.g002
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e19454Figure 3. Receiver-operating characteristic curves for models predicting diagnosis psoriasis. The AUC for wGRS is significantly greater
than AUC for cGRS, p=2.13610
28. The AUC for HLA-C alone (rs10484554) is not statistically different than the AUC for cGRS, and no worse than the
AUC for the wGRS with HLA-C excluded, p=0.18. AUC: area under curve. wGRS: weighted genetic risk score. cGRS: counted genetic risk score.
doi:10.1371/journal.pone.0019454.g003
Table 3. Association of wGRS with psoriasis subphenotypes.
N Reference phenotype Test phenotype OR* (95% CI) p-value*
Family history 514 No Yes ($1 first-degree relatives
affected)
1.340(1.050–1.723) 0.020
Age onset 537 #30 yrs .30 yrs 0.559(0.433–0.714) 4.91E-06
Psoriatic arthritis 560 No Yes 0.849(0.688–1.043) 0.121
Psoriasis type 557 plaque guttate 1.342(0.923–1.851) 0.072
*P-value and ORs were adjusted for first 4 principal components and gender.
OR: Odds ratio.
95%CI: 95% confidence intervals.
doi:10.1371/journal.pone.0019454.t003
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surrogate for genetic predisposition, it is not surprising that a
higher GRS was seen in cases with affected first degree relatives. A
marginal significance (p=0.072) was observed between the wGRS
and guttate psoriasis. This could be explained by the stronger
association of HLA-Cw6 with guttate psoriasis compared to
plaque psoriasis [34]. We did not detect an association between
the wGRS and PsA. This may be in part due to the small sample
sizes of the subgroup analyses. In addition, since the GRS SNPs
used in this study were identified based on genetic studies of
psoriasis and not PsA per se, lack of association with PsA may
simply indicate that the present SNPs do not account for genetic
susceptibility to the arthritic component.
The estimated proportion of genetic variation explained by
the 10 included SNPs in this study was11.6%, including 6.7%
due to HLA-C. This suggests that many additional suscepti-
bility loci for psoriasis remain to be discovered. Similar results
have been reported in other complex diseases. For example,
the proportion of heritability explained by known common
SNPs for Crohn’s disease, systemic lupus erythematosus and
type 2 diabetes was estimated to be around 20%, 15% and 6%,
respectively [35]. One hypothesis is that rare variants with
higher penetrance, not covered by the present genotyping,
might be able to explain the remaining heritability [36].
Searching for such genetic factors are underway thanks to
advances in next generation sequencing technologies [15].
Furthermore, although the wGRS is highly significantly
associated with psoriasis susceptibility, the predictive capabil-
ity is seemingly modest (AUC for ROC curve 72.0%). It will
be interesting to see whether the discriminatory accuracy can
be improved as additional rare variants in psoriasis are
included.
Several limitations to this study need to be acknowledged. First,
although we captured the most significant psoriasis loci known to
date for calculation of the GRS, we did not include all known
psoriasis loci. For example, human b defensin (HBD) was not
evaluated in this study since we were unable to identify a proxy
SNP for HBD copy number[37]. Additionally, during the
preparation this manuscript, several novel psoriasis loci were
identified by very recent genome-wide association studies but not
included in this study [38–41]. Among them, TRAF3IP2 was
shown to be the most reproducibly associated locus and showed a
psoriasis odds ratio of 1.70. However, none of the newly identified
loci is estimated to explain more than 1% of the heritability.
Inclusion of these additional loci to the SNPs described in our
model results in an estimated proportion of heritability explained
of 15%. Second, to increase the robustness of our control data set,
we included a number of controls from the public iControlDB
database. However, we used a panel of European AIMs to correct
for potential population stratification. Moreover, when we
conducted the association analysis removing the iControlDB
subjects, we obtained similar results with respect to the direction of
association and magnitude of the odds ratio for each SNP (data
not shown). Third, two of the GRS SNPs in the iControlDB
dataset were imputed rather than directly genotyped and in two
instances we used proxy SNPs for the originally reported variants.
Although using imputed or proxy SNPs might lead to less accurate
results, we ensured that only SNPs with high imputation
confidence .98% and proxy SNPs with r
2 .0.9 were included
in final analysis. Fourth, only Caucasians were included in this
study. Thus, the characteristics of the GRS calculated here may
not applicable to other ethnic populations. Fifth, our prediction
model is based on the same data used to construct the model,
which may lead to overfitting and overestimation of the AUC.
Finally, this was not a prospectively-designed study, and thus we
were unable to truly examine the discriminatory power of these
SNPs.
In summary, we found that a GRS combining 10 psoriasis risk
loci was significantly associated with an increased risk of psoriasis.
The weighted GRS approach increased the power in discrimina-
tory accuracy, compared to the counted GRS and any of the risk
alleles considered alone. A higher GRS was associated with early-
onset of disease and positive family history. The 10 risk loci
account for only 11.6% of the genetic variance in psoriasis,
suggesting that additional susceptibility alleles remain to be
identified.
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Figure S1 Correlation among family members. The nature of
intra-family vs inter-family variation was investigated by plotting
wGRSfamily, affected against wGRSfamily, unaffected in each family. A
strong positive correlation was observed between wGRS of
unaffected subjects and affected subjects within each fa-
mily(R=0.299, p=4.58610
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Table S1 SNPs used to estimate psoriasis genetic risk score:
references, proxies and imputed SNPs.
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Table 4. The percentage of genetic variance explained by
selected SNPs.
Chr Gene SNP Additive genetic variance explained*
1 IL23R rs11209026 0.0045
1 LCE3C/3D del rs4112788 0.0083
5 IL13 rs20541 0.0002
5 TNIP1/ANXA6 rs17728338 0.0101
5 IL12B rs3213094 0.0127
6 CDKAL1 rs6908425 0.0023
6 HLA-C rs10484554 0.0666
6 TNFAIP3 rs610604 0.0011
12 IL23A/STAT2 rs2066808 0.0089
20 ZNF313 rs6125829 0.0013
*The percentage of variance explained was estimated under liability threshold
model.
Totally, the selected 10 SNPs could explain11.6% of genetic variance.
SNP: Single nucleotide polymorphism.
Chr: chromosome.
doi:10.1371/journal.pone.0019454.t004
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